Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lymphocyte profile in peripheral blood of patients with multiple myeloma

T. Dekojová, H. Gmucová, D. Macečková, R. Klieber, P. Ostašov, M. Leba, T. Vlas, A. Jungová, VS. Caputo, M. Čedíková, D. Lysák, P. Jindra, M. Holubová

. 2024 ; 103 (12) : 5615-5625. [pub] 20240604

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010587

Grantová podpora
FNPl, 00669806 Ministerstvo Zdravotnictví Ceské Republiky
SVV 260 561 Charles University
Cooperatio, research area ONCO Charles University

Multiple myeloma (MM) is a disease which remains incurable. One of the main reasons is a weakened immune system that allows MM cells to survive. Therefore, the current research is focused on the study of immune system imbalance in MM to find the most effective immunotherapy strategies. Aiming to identify the key points of immune failure in MM patients, we analysed peripheral lymphocytes subsets from MM patients (n = 57) at various stages of the disease course and healthy individuals (HI, n = 15) focusing on T, NK, iNKT, B cells and NK-cell cytokines. Our analysis revealed that MM patients exhibited immune alterations in all studied immune subsets. Compared to HI, MM patients had a significantly lower proportion of CD4 + T cells (19.55% vs. 40.85%; p < 0.001) and CD4 + iNKT cells (18.8% vs. 40%; p < 0.001), within B cells an increased proportion of CD21LCD38L subset (4.5% vs. 0.4%; p < 0.01) and decreased level of memory cells (unswitched 6.1% vs. 14.7%; p < 0.001 and switched 7.8% vs. 11.2%; NS), NK cells displaying signs of activation and exhaustion characterised by a more than 2-fold increase in SLAMF7 MFI (p < 0.001), decreased expression of NKG2D (MFI) and NKp46 (%) on CD16 + 56 + and CD16 + 56- subset respectively (p < 0.05), Effective immunotherapy needs to consider these immune defects and monitoring of the immune status of MM patients is essential to define better interventions in the future.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010587
003      
CZ-PrNML
005      
20250429134505.0
007      
ta
008      
250415s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-024-05820-x $2 doi
035    __
$a (PubMed)38832999
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Dekojová, Tereza $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic
245    10
$a Lymphocyte profile in peripheral blood of patients with multiple myeloma / $c T. Dekojová, H. Gmucová, D. Macečková, R. Klieber, P. Ostašov, M. Leba, T. Vlas, A. Jungová, VS. Caputo, M. Čedíková, D. Lysák, P. Jindra, M. Holubová
520    9_
$a Multiple myeloma (MM) is a disease which remains incurable. One of the main reasons is a weakened immune system that allows MM cells to survive. Therefore, the current research is focused on the study of immune system imbalance in MM to find the most effective immunotherapy strategies. Aiming to identify the key points of immune failure in MM patients, we analysed peripheral lymphocytes subsets from MM patients (n = 57) at various stages of the disease course and healthy individuals (HI, n = 15) focusing on T, NK, iNKT, B cells and NK-cell cytokines. Our analysis revealed that MM patients exhibited immune alterations in all studied immune subsets. Compared to HI, MM patients had a significantly lower proportion of CD4 + T cells (19.55% vs. 40.85%; p < 0.001) and CD4 + iNKT cells (18.8% vs. 40%; p < 0.001), within B cells an increased proportion of CD21LCD38L subset (4.5% vs. 0.4%; p < 0.01) and decreased level of memory cells (unswitched 6.1% vs. 14.7%; p < 0.001 and switched 7.8% vs. 11.2%; NS), NK cells displaying signs of activation and exhaustion characterised by a more than 2-fold increase in SLAMF7 MFI (p < 0.001), decreased expression of NKG2D (MFI) and NKp46 (%) on CD16 + 56 + and CD16 + 56- subset respectively (p < 0.05), Effective immunotherapy needs to consider these immune defects and monitoring of the immune status of MM patients is essential to define better interventions in the future.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x krev $x imunologie $x terapie $7 D009101
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a buňky NK $x imunologie $7 D007694
650    _2
$a dospělí $7 D000328
650    _2
$a podskupiny lymfocytů $x imunologie $7 D016131
650    _2
$a cytokiny $x krev $7 D016207
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a B-lymfocyty $x imunologie $7 D001402
650    _2
$a NKT buňky $x imunologie $7 D055611
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gmucová, Hana $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic
700    1_
$a Macečková, Diana $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic
700    1_
$a Klieber, Robin $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic
700    1_
$a Ostašov, Pavel $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic
700    1_
$a Leba, Martin $u Faculty of Applied Science, University of West Bohemia, Pilsen, 301 00, Czech Republic
700    1_
$a Vlas, Tomáš $u Institute of Allergology and Immunology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic
700    1_
$a Jungová, Alexandra $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic
700    1_
$a Caputo, Valentina S $u Cancer Biology and Therapy laboratory, School of Applied Sciences, London South Bank University, London, UK
700    1_
$a Čedíková, Miroslava $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic
700    1_
$a Lysák, Daniel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic
700    1_
$a Jindra, Pavel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic
700    1_
$a Holubová, Monika $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, 323 00, Czech Republic. monika.holubova@lfp.cuni.cz $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic. monika.holubova@lfp.cuni.cz
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 103, č. 12 (2024), s. 5615-5625
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38832999 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134500 $b ABA008
999    __
$a ok $b bmc $g 2311767 $s 1247668
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 103 $c 12 $d 5615-5625 $e 20240604 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a FNPl, 00669806 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a SVV 260 561 $p Charles University
GRA    __
$a Cooperatio, research area ONCO $p Charles University
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace